KR20220068266A - 자가소화의 치료용의 조성물 - Google Patents

자가소화의 치료용의 조성물 Download PDF

Info

Publication number
KR20220068266A
KR20220068266A KR1020227015575A KR20227015575A KR20220068266A KR 20220068266 A KR20220068266 A KR 20220068266A KR 1020227015575 A KR1020227015575 A KR 1020227015575A KR 20227015575 A KR20227015575 A KR 20227015575A KR 20220068266 A KR20220068266 A KR 20220068266A
Authority
KR
South Korea
Prior art keywords
peg
glucose
shock
composition
tranexamic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020227015575A
Other languages
English (en)
Korean (ko)
Inventor
토마스 할램
로빈 잭맨
존 로덴리스
Original Assignee
리딩 바이오사이언시즈, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리딩 바이오사이언시즈, 인크. filed Critical 리딩 바이오사이언시즈, 인크.
Publication of KR20220068266A publication Critical patent/KR20220068266A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020227015575A 2014-03-25 2015-03-24 자가소화의 치료용의 조성물 Ceased KR20220068266A (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201461970247P 2014-03-25 2014-03-25
US61/970,247 2014-03-25
US201462019007P 2014-06-30 2014-06-30
US62/019,007 2014-06-30
PCT/US2015/022198 WO2015148474A1 (en) 2014-03-25 2015-03-24 Compositions for the treatment of autodigestion
KR1020167027915A KR102397379B1 (ko) 2014-03-25 2015-03-24 자가소화의 치료용의 조성물

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020167027915A Division KR102397379B1 (ko) 2014-03-25 2015-03-24 자가소화의 치료용의 조성물

Publications (1)

Publication Number Publication Date
KR20220068266A true KR20220068266A (ko) 2022-05-25

Family

ID=54188811

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020227015575A Ceased KR20220068266A (ko) 2014-03-25 2015-03-24 자가소화의 치료용의 조성물
KR1020167027915A Expired - Fee Related KR102397379B1 (ko) 2014-03-25 2015-03-24 자가소화의 치료용의 조성물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020167027915A Expired - Fee Related KR102397379B1 (ko) 2014-03-25 2015-03-24 자가소화의 치료용의 조성물

Country Status (14)

Country Link
US (4) US9314442B2 (https=)
EP (1) EP3122349B1 (https=)
JP (1) JP6648106B2 (https=)
KR (2) KR20220068266A (https=)
CN (3) CN112807325A (https=)
AU (1) AU2015236283B2 (https=)
CA (1) CA2942358C (https=)
DK (1) DK3122349T3 (https=)
ES (1) ES2906262T3 (https=)
MX (1) MX376176B (https=)
PL (1) PL3122349T3 (https=)
PT (1) PT3122349T (https=)
TW (2) TWI554269B (https=)
WO (1) WO2015148474A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9504736B2 (en) 2010-09-23 2016-11-29 The Regents Of The University Of California Administration of serine protease inhibitors to the stomach
CN112807325A (zh) 2014-03-25 2021-05-18 恒翼生物医药科技(上海)有限公司 用于治疗自身消化的组合物
CA3010986A1 (en) 2016-01-11 2017-07-20 Leading BioSciences, Inc. Compositions and methods for treating and preventing adhesions and ileus
US20200323803A1 (en) * 2017-10-24 2020-10-15 Leading BioSciences, Inc. Compositions and methods for glucose control
US11666532B2 (en) 2018-01-19 2023-06-06 Hyloris Developments Sa Tranexamic acid oral solution
CN110730413A (zh) * 2018-06-29 2020-01-24 阿里巴巴集团控股有限公司 一种终端定位方法和装置
US10980757B2 (en) 2018-09-06 2021-04-20 RTU Pharma SA Ready-to-use tranexamic acid intravenous solution

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4465662A (en) 1980-04-08 1984-08-14 Lion Corporation Oral compositions of tranexamic acid and carvone
US20090017114A1 (en) 2003-07-31 2009-01-15 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations with reduced adverse effects

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3496158B2 (ja) 1993-01-26 2004-02-09 東洋カプセル株式会社 トラネキサム酸配合ゼラチンカプセル製剤
US5578568A (en) 1994-04-22 1996-11-26 Xoma Corporation Method of treating conditions associated with intestinal ischemia/reperfusion
DE19617369A1 (de) 1996-04-30 1997-11-06 Immuno Ag Lagerstabile Fibrinogen-Präparate
JP3940209B2 (ja) 1996-11-14 2007-07-04 株式会社資生堂 可溶化化粧料
US6121232A (en) 1997-01-31 2000-09-19 Omrix Biopharmaceuticals Sa Stabilized mixture comprising fibrinogen
CA2301921A1 (en) 1997-08-20 1999-02-25 John Graham Goddard Compositions containing polyethylene glycol and uses thereof
TWI243687B (en) 1998-04-21 2005-11-21 Teijin Ltd Pharmaceutical composition for application to mucosa
DE10025001A1 (de) 2000-05-22 2001-11-29 Aventis Behring Gmbh Gewebekleber mit verbesserten anti-adhäsiven Eigenschaften
US7276235B2 (en) 1998-11-18 2007-10-02 Zlb Behring Gmbh Tissue glue with improved antiadhesive properties
AU1794801A (en) 1999-11-24 2001-06-04 Regents Of The University Of California, The Method for treatment and prevention of physiological shock
US6708822B1 (en) 1999-11-30 2004-03-23 Cutispharma, Inc. Compositions and kits for compounding pharmaceuticals
US20030144212A1 (en) 2000-07-06 2003-07-31 Hoffman Keith B Use of serine protease inhibitors to inhibit pathophysiology and neuropathology in a host
JP4044748B2 (ja) 2001-10-17 2008-02-06 サンスター株式会社 口腔用液体組成物
US20040018984A1 (en) 2002-07-17 2004-01-29 Mizuo Miyazaki Methods for preventing adhesion formation using protease inhibitors
GB0224909D0 (en) 2002-10-25 2002-12-04 Norgine Europe Bv Colon cleansing compositions
JP5271475B2 (ja) 2002-11-26 2013-08-21 ザ ユニヴァーシティー オヴ シカゴ 微生物媒介上皮疾患の予防及び治療のための材料並びに方法
JP2005068076A (ja) 2003-08-25 2005-03-17 Tendou Seiyaku Kk トラネキサム酸類を含む外用液剤および清拭剤
US20090215898A1 (en) 2004-03-04 2009-08-27 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations
EP1744767A4 (en) 2004-04-20 2008-08-13 Univ Chicago THERAPEUTIC DELIVERY SYSTEM WITH PEG-LIKE CONNECTION WITH HIGH MOLECULAR WEIGHT
CA2610951A1 (en) 2005-06-03 2006-12-14 The University Of Chicago Modulation of microbial pathogen-host cell interactions
CA2609985A1 (en) 2005-06-03 2007-05-10 The University Of Chicago Modulation of cell barrier dysfunction
US20080194611A1 (en) 2005-06-03 2008-08-14 Alverdy John C Modulation of Cell Barrier Dysfunction
WO2007101264A2 (en) 2006-02-28 2007-09-07 The University Of Chicago Method for treating endothelial and epithelial cell disorders by administering high molecular weight peg-like compounds
JP5465824B2 (ja) 2006-03-24 2014-04-09 第一三共ヘルスケア株式会社 医薬用製剤およびその製造方法
US20100179091A1 (en) 2007-02-20 2010-07-15 The Regents Of The University Of California Treatment of Conditions Related to Shock
US8252302B2 (en) 2007-06-11 2012-08-28 Edge Therapeutics, Inc. Methods and compositions to treat hemorrhagic conditions of the brain
JP5093841B2 (ja) 2007-07-12 2012-12-12 株式会社 資生堂 不織布含浸化粧料
US9272034B2 (en) 2007-10-04 2016-03-01 The Regents Of The University Of California Treatment of conditions related to shock
WO2010087874A1 (en) 2009-01-28 2010-08-05 Anazyme, Llc Compositions and methods for diagnosis of shock
WO2009132149A2 (en) 2008-04-22 2009-10-29 The Regents Of The University Of California Treatment of conditions related to cecal ligation shock
WO2009137672A1 (en) 2008-05-07 2009-11-12 Salix Pharmaceuticals, Ltd. Methods of treating bowel disease by administering a bowel cleanser and an antibiotic
US7635707B1 (en) * 2008-11-10 2009-12-22 Intermune, Inc. Pirfenidone treatment for patients with atypical liver function
ZA201107285B (en) 2009-03-06 2012-12-27 Delivtx Inc Microencapsulated bioactive agents for oral delivery and methods of the thereof
MX2011009988A (es) 2009-03-23 2011-11-18 Univ Chicago Metodos para la prevencion y el tratamiento de trastornos epiteliales inducidos por radiaciones.
US8852155B2 (en) * 2009-08-12 2014-10-07 Medimetrics Personalized Drug Delivery Medicine reservoir for drug delivery device
WO2011028234A1 (en) 2009-09-04 2011-03-10 Xenoport, Inc. Uses of acyloxyalkyl carbamate prodrugs of tranexamic acid
US9504736B2 (en) * 2010-09-23 2016-11-29 The Regents Of The University Of California Administration of serine protease inhibitors to the stomach
CN103237558A (zh) 2010-10-02 2013-08-07 加利福尼亚大学董事会 最小化肠功能障碍
JP6148454B2 (ja) * 2011-11-11 2017-06-14 ロート製薬株式会社 トラネキサム酸を含む外用及び内服用組成物
ES2375784B1 (es) 2011-12-22 2013-01-24 Laboratorios Kin S.A. Gel de ácido tranexámico
CN103565743B (zh) * 2012-07-23 2016-06-22 上海市徐汇区中心医院 氨甲环酸皮肤外用纳米制剂及其制备方法和用途
US9937199B2 (en) 2012-08-17 2018-04-10 The University Of Chicago Materials and methods for preventing and treating anastomotic leaks
CN103054861A (zh) * 2012-12-29 2013-04-24 北京阜康仁生物制药科技有限公司 一种含氨甲环酸的复方固体制剂
US20140271923A1 (en) 2013-03-14 2014-09-18 Christopher Brian Reid Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions
CN112807325A (zh) 2014-03-25 2021-05-18 恒翼生物医药科技(上海)有限公司 用于治疗自身消化的组合物
US20150297619A1 (en) 2014-04-17 2015-10-22 The Regents Of The University Of California Methods and compositions for preserving the mucosal barrier

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4465662A (en) 1980-04-08 1984-08-14 Lion Corporation Oral compositions of tranexamic acid and carvone
US20090017114A1 (en) 2003-07-31 2009-01-15 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations with reduced adverse effects

Also Published As

Publication number Publication date
US9775821B2 (en) 2017-10-03
CN106572987B (zh) 2021-02-12
DK3122349T3 (da) 2022-02-14
JP2017515888A (ja) 2017-06-15
KR102397379B1 (ko) 2022-05-13
PL3122349T3 (pl) 2022-02-28
CN106572987A (zh) 2017-04-19
WO2015148474A1 (en) 2015-10-01
JP6648106B2 (ja) 2020-02-14
EP3122349A4 (en) 2017-10-11
MX376176B (es) 2025-03-07
KR20170031084A (ko) 2017-03-20
CN112641771B (zh) 2022-04-15
TW201538154A (zh) 2015-10-16
CA2942358C (en) 2023-03-28
MX2016012248A (es) 2017-04-27
TWI669114B (zh) 2019-08-21
PT3122349T (pt) 2022-02-07
US9314442B2 (en) 2016-04-19
EP3122349B1 (en) 2021-12-22
CA2942358A1 (en) 2015-10-01
US20160263064A1 (en) 2016-09-15
US20220054439A1 (en) 2022-02-24
US20180000765A1 (en) 2018-01-04
US11123317B2 (en) 2021-09-21
CN112641771A (zh) 2021-04-13
AU2015236283B2 (en) 2020-05-07
ES2906262T3 (es) 2022-04-13
EP3122349A1 (en) 2017-02-01
TW201707697A (zh) 2017-03-01
US20150272914A1 (en) 2015-10-01
AU2015236283A1 (en) 2016-09-29
TWI554269B (zh) 2016-10-21
CN112807325A (zh) 2021-05-18

Similar Documents

Publication Publication Date Title
KR102397379B1 (ko) 자가소화의 치료용의 조성물
CN105899213B (zh) 氧化胆固醇硫酸酯(ocs)的方法
KR20190032529A (ko) 산소화 콜레스테롤 술페이트, 및 폴리알킬렌 글리콜, 카르복시메틸 셀룰로오스 및 폴리옥실글리세리드 중 적어도 하나를 포함하는 조성물
HK40049334A (en) Compositions for the treatment of autodigestion
HK40049334B (en) Compositions for the treatment of autodigestion
HK40051381A (en) Compositions for the treatment of autodigestion
Tubili 0.9% saline solution:“physiological” or “unphysiological”?
Hussain et al. Clinical Study Direct Comparison of the Safety and Efficacy of Ferric Carboxymaltose versus Iron Dextran in Patients with Iron Deficiency Anemia

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20220509

Application number text: 1020167027915

Filing date: 20161007

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220608

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220701

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20230403

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20220701

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I